Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01173874 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone
A Phase 3 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
NCT01173874 is a Phase 3 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 120 participants.
The verdict
NCT01173874, a Phase 3 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
Study Summary
The investigators hypothesize that cognitive remediation will be superior to the active control group on the change from baseline to study end point of cognitive remediation phase on both co-primary outcome measures (standardized composite MATRICS score and Cognitive Assessment Interview).
Interventions
- DRUG Cognitive Remediation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2010-07 |
| Est. Completion | 2013-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01173874
The ClinicalTrials.gov registry entry for NCT01173874 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cognitive Remediation is the first listed.
NCT01173874 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01173874 about?
NCT01173874 is a clinical study titled "Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone". The investigators hypothesize that cognitive remediation will be superior to the active control group on the change from baseline to study end point of cognitive remediation phase on both co-primary outcome measures (standardized composite MATRICS score and Cognitive Assessment Interview).
What is the current status of trial NCT01173874?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2010-07. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01173874?
The interventions under investigation include: Cognitive Remediation (DRUG).
Who is sponsoring clinical trial NCT01173874?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.